Cedar Hill Associates’s Novartis NVS Stock Holding History

Cedar Hill Associates’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-3,241	Closed	-$248K	–	154
2017 Q3	$248K	Buy	+3,241	New	+$245K	0.04%	135

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cedar Hill Associates's NVS Position: Q4 2017 in Review

Cedar Hill Associates sold out of Novartis (NVS) in Q4 2017, closing a stake of 3,241 shares — an estimated $248K sold.

Cedar Hill Associates first reported a position in NVS in Q3 2017 and held it in 1 quarter. The position peaked at $248K in Q3 2017. 1,006 funds tracked by Wall St. Rank hold NVS as of Q4 2017.

Cedar Hill Associates reported no remaining Novartis position as of Q4 2017 after selling out during the quarter.
Cedar Hill Associates sold 3,241 Novartis shares in Q4 2017, an estimated $248K.
Cedar Hill Associates first reported a position in Novartis in Q3 2017 and held it in 1 quarter.
Cedar Hill Associates's Novartis position peaked at $248K in Q3 2017.
1,006 funds tracked by Wall St. Rank held Novartis as of Q4 2017.

Based on Cedar Hill Associates's 13F filing for Q4 2017, filed 21 Feb 2018.